P/B
1,5
SIGA Technologies
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
$247.9M
Market Cap • 9/25/2026
1995
(31 years)
Founded
1997
(29 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
4,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,3
EPS
—
Market Cap
Market Cap
247,9M
EV
130,3M
EV/Revenue
2,4
EV/EBITDA
-12,4
EV/EBIT
-11,7
Payout
Dividend Per Share
0,6
Dividend Yield
17,6%
Buyback Yield
0,3%
Total Yield
18%
Dividend Yield 5Y
11,4%
Payout
-1563,1%
Retained Earnings
-78M
Profitability
Gross Margin
54,4%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
38,1%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,9%
% Goodwill
0,5%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-10,9%
Leverage
N.D./EBITDA
11,1
Debt/Equity
0%
Current Ratio
21,7
Quick Ratio
15,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!